Pathology & Laboratory Medicine

Timing of Adjuvant Fractionated Stereotactic Radiosurgery Affects Local Control of Resected Brain Metastases.

O'Brien DARoth, Poppas P, Kaye SM, Mahase SS, An A, Christos PJ, Liechty B, Pisapia D, Ramakrishna R, A Wernicke G et al..  2021.  Timing of Adjuvant Fractionated Stereotactic Radiosurgery Affects Local Control of Resected Brain Metastases.. Pract Radiat Oncol. 11(3):e267-e275.

Time to administration of stereotactic radiosurgery to the cavity after surgery for brain metastases: a real-world analysis.

O'Brien DARoth, Kaye SM, Poppas PJ, Mahase SS, An A, Christos PJ, Liechty B, Pisapia D, Ramakrishna R, Wernicke AG et al..  2021.  Time to administration of stereotactic radiosurgery to the cavity after surgery for brain metastases: a real-world analysis.. J Neurosurg. :1-11.

A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion.

Khosravi P, Lysandrou M, Eljalby M, Li Q, Kazemi E, Zisimopoulos P, Sigaras A, Brendel M, Barnes J, Ricketts C et al..  2021.  A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion.. J Magn Reson Imaging. 54(2):462-471.

Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.

Beg S, Bareja R, Ohara K, Eng KWha, Wilkes DC, Pisapia DJ, Zoughbi WAl, Kudman S, Zhang W, Rao R et al..  2021.  Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.. Transl Oncol. 14(1):100944.

Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.

Grbesa I, Augello MA, Liu D, McNally DR, Gaffney CD, Huang D, Lin K, Ivenitsky D, Goueli R, Robinson BD et al..  2021.  Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.. Cell Rep. 36(10):109625.

Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.. Nat Commun. 12(1):3372.